ITM2A and acute myeloid leukemia: With studies that reported that loss of ITM2A was a poor OS factor of cervical cancer (33), hepatocellular carcinoma (34), and acute myeloid leukemia (23), together with the fact that ITM2A has been observed to significantly decrease in those carcinoma types, we implied that ITM2A might be a novel tumor suppressor in those carcinomas that included breast cancer.